Literature DB >> 11819277

Transduction of human hepatocellular carcinoma cells with human alpha-interferon gene via retroviral vector.

Shu-Bing Qian, Shi-Shu Chen.   

Abstract

AIM:To investigate the therapeutic potential of gamma interferon (IFN-alpha) genemodified human hepatocellular carcinoma (HCC) cells.
METHODS: The IFN-alpha gene was introduced retrovirally into four HCC cell lines.Secreted IFN-alpha activity was assessed using bioassay. The expression of MHC molecules was detected by FACS.Tumorigenicity was analysed by tumor formation in nude mice.
RESULTS: Four IFN-alpha gene transduced HCC cell lines secreted different amounts of IFN-alpha, as in the same case of five clones derived from one HCC cell line. Transduction with IFN-alpha caused significant increase in the expression of major histocompatibility complex (MHC) antigens on HCC cells. The expression of HLA class I was increased by 2-3 times in terms of mean fluorescence intensities, while for class II expression, the percentage of positive cells augmented from < 10% to &amp;lg 50%. When equal amount of tumor cells were injected into nude mice, the tumor igenicity some transduced cells decreased dramantically.
CONCLUSION: IFN-alpha gene transduction can convert weakly imunogenic HCC cells to activate antitumor immune response, and further pave the way for the future use of such gene modified tumor cells as a modality for the cancer immunotherapy.

Entities:  

Year:  1998        PMID: 11819277      PMCID: PMC4723458          DOI: 10.3748/wjg.v4.i3.210

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  9 in total

1.  Effects of interferon-gamma on the activation of human T lymphocytes.

Authors:  J P Siegel
Journal:  Cell Immunol       Date:  1988-02       Impact factor: 4.868

2.  Transduction of human renal carcinoma cells with human gamma-interferon gene via retroviral vector.

Authors:  S K Nayak; T McCallister; L J Han; R Gangavalli; J Barber; R O Dillman
Journal:  Cancer Gene Ther       Date:  1996 May-Jun       Impact factor: 5.987

Review 3.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance.

Authors:  S Ferrone; F M Marincola
Journal:  Immunol Today       Date:  1995-10

4.  Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.

Authors:  B Gansbacher; R Bannerji; B Daniels; K Zier; K Cronin; E Gilboa
Journal:  Cancer Res       Date:  1990-12-15       Impact factor: 12.701

Review 5.  Immunotherapy of cancer using cytokine gene-modified tumor vaccines.

Authors:  E Gilboa; H K Lyerly; J Vieweg; S Saito
Journal:  Semin Cancer Biol       Date:  1994-12       Impact factor: 15.707

6.  Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.

Authors:  M Ogasawara; S A Rosenberg
Journal:  Cancer Res       Date:  1993-08-01       Impact factor: 12.701

Review 7.  Transfer of genes to humans: early lessons and obstacles to success.

Authors:  R G Crystal
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

8.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.

Authors:  B Gansbacher; K Zier; B Daniels; K Cronin; R Bannerji; E Gilboa
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

9.  A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.

Authors:  N P Restifo; P J Spiess; S E Karp; J J Mulé; S A Rosenberg
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

  9 in total
  6 in total

1.  Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B.

Authors:  L Zhuang; J You; B Z Tang; S Y Ding; K H Yan; D Peng; Y M Zhang; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B.

Authors:  J You; L Zhuang; B Z Tang; W B Yang; S Y Ding; W Li; R X Wu; H L Zhang; Y M Zhang; S M Yan; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

3.  Percutaneous transsplenic embolization of esophageal and gastrio-fundal varices in 18 patients.

Authors:  G Q Gong; X L Wang; J H Wang; Z P Yan; J M Cheng; S Qian; Y Chen
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

4.  Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.

Authors:  Jing You; Lin Zhuang; Hong-Ying Cheng; Shou-Ming Yan; Lan Yu; Jun-Hua Huang; Bao-Zhang Tang; Meng-Ling Huang; Yong-Liang Ma; Virasakdi Chongsuvivatwong; Hutcha Sriplung; Alan Geater; Yan-Wei Qiao; Rong-Xue Wu
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

5.  Field population-based blocking treatment of esophageal epithelia dysplasia.

Authors:  Jun Hou; Pei-Zhong Lin; Zhi-Feng Chen; Zhen-Wei Ding; Shao-Sheng Li; Fan-Shu Men; Li-Ping Guo; Yu-Tong He; Chui-Yun Qiao; Chui-Lan Guo; Jian-Ping Duan; Deng-Gui Wen
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

6.  Prevention of hepatocellular carcinoma in mice by IL-2 and B7-1 genes co-transfected liver cancer cell vaccines.

Authors:  Ning-Ling Ge; Sheng-Long Ye; Ning Zheng; Rui-Xia Sun; Yin-Kun Liu; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.